ORC ID , Tomasz Siwek1, Tomasz Ołdak2, Katarzyna Jezierska-Woźniak4, Dominika Gładysz2, Wojciech Maksymowicz5">
  • Users Online: 1529
  • Home
  • Print this page
  • Email this page
RESEARCH ARTICLE
Year : 2019  |  Volume : 14  |  Issue : 2  |  Page : 313-318

Safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy


1 Department of Neurology and Neurosurgery, School of Medicine, Collegium Medicum - University of Warmia and Mazury in Olsztyn; University Clinical Hospital in Olsztyn; Instytut Terapii Komórkowych w Olsztynie (Cell Therapies Institute, FamiCord Group), Olsztyn, Poland
2 Polski Bank Komórek Macierzystych (PBKM, FamiCord Group), Warszawa, Poland
3 Department of Psychology, Clinical Logopedics and Social Science in Medicine, Faculty of Health Sciences, Collegium Medicum - University of Warmia and Mazury in Olsztyn; Instytut Terapii Komórkowych w Olsztynie (Cell Therapies Institute, FamiCord Group), Olsztyn, Poland
4 Department of Neurology and Neurosurgery, Laboratory of Regenerative Medicine, School of Medicine, Collegium Medicum-University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
5 Department of Neurology and Neurosurgery, School of Medicine, Collegium Medicum - University of Warmia and Mazury in Olsztyn; University Clinical Hospital in Olsztyn, Olsztyn, Poland

Correspondence Address:
Stanisław Maksymowicz
Department of Psychology, Clinical Logopedics and Social Science in Medicine, Faculty of Health Sciences, Collegium Medicum - University of Warmia and Mazury in Olsztyn; Instytut Terapii Komórkowych w Olsztynie (Cell Therapies Institute, FamiCord Group), Olsztyn
Poland
Login to access the Email id

Source of Support: This research was supported by Instytut Terapii Komórkowych w Olsztynie (Cell Therapies Institute, FamiCord Group) in Olsztyn (to MB, SM, and TS), Conflict of Interest: None


DOI: 10.4103/1673-5374.243723

Rights and Permissions

Animal experiments have confirmed that mesenchymal stem cells can inhibit motor neuron apoptosis and inflammatory factor expression and increase neurotrophic factor expression. Therefore, mesenchymal stem cells have been shown to exhibit prospects in the treatment of amyotrophic lateral sclerosis. However, the safety of their clinical application needs to be validated. To investigate the safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy, 43 patients (16 females and 27 males, mean age of 57.3 years) received an average dose of 0.42 × 106 cells/kg through intrathecal administration at the cervical, thoracic or lumbar region depending on the clinical symptoms. There was a 2 month interval between two injections. The adverse events occurring during a 6-month treatment period were evaluated. No adverse events occurred. Headache occurred in one case only after first injection of stem cells. This suggests that intrathecal injection of Wharton’s Jelly-derived mesenchymal stem cells is well tolerated in patients with amyotrophic lateral sclerosis. This study was approved by the Bioethical Committee of School of Medicine, University of Warmia and Mazury in Olsztyn, Poland (approval No. 36/2014 and approval No. 8/2016). This study was registered with the ClinicalTrials.gov (identifier: NCT02881476) on August 29, 2016.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2502    
    Printed12    
    Emailed0    
    PDF Downloaded287    
    Comments [Add]    
    Cited by others 6    

Recommend this journal